Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Prone breast intensity modulated radiation therapy: 5-year results.

Osa EO, DeWyngaert K, Roses D, Speyer J, Guth A, Axelrod D, Fenton Kerimian M, Goldberg JD, Formenti SC.

Int J Radiat Oncol Biol Phys. 2014 Jul 15;89(4):899-906. doi: 10.1016/j.ijrobp.2014.03.036. Epub 2014 May 24.

2.

Anti-Mullerian hormone: determination of ovarian reserve in early breast cancer patients.

Bozza C, Puglisi F, Lambertini M, Osa EO, Manno M, Del Mastro L.

Endocr Relat Cancer. 2014 Jan 21;21(1):R51-65. doi: 10.1530/ERC-13-0335. Print 2014 Feb. Review.

PMID:
24292601
3.

Primary therapy in breast cancer: what have we learned from landmark trials?

Bozza C, Osa EO, Puglisi F.

Womens Health (Lond). 2013 Nov;9(6):583-93. doi: 10.2217/whe.13.55. Review.

PMID:
24161310
4.

Making capecitabine targeted therapy for breast cancer: which is the role of thymidine phosphorylase?

Bonotto M, Bozza C, Di Loreto C, Osa EO, Poletto E, Puglisi F.

Clin Breast Cancer. 2013 Jun;13(3):167-72. doi: 10.1016/j.clbc.2012.10.002. Epub 2012 Dec 5. Review.

PMID:
23218471
5.

Dose to craniofacial region through portal imaging of pediatric brain tumors.

Hitchen CJ, Osa EO, Dewyngaert JK, Chang J, Narayana A.

J Appl Clin Med Phys. 2012 Jan 5;13(1):3385. doi: 10.1120/jacmp.v13i1.3385.

6.

Diminished visibility of cerebral venous vasculature in multiple sclerosis by susceptibility-weighted imaging at 3.0 Tesla.

Ge Y, Zohrabian VM, Osa EO, Xu J, Jaggi H, Herbert J, Haacke EM, Grossman RI.

J Magn Reson Imaging. 2009 May;29(5):1190-4. doi: 10.1002/jmri.21758.

7.

Selective side-chain modification of cysteine and arginine residues blocks pathogenic activity of HIV-1-Tat functional peptides.

Devadas K, Boykins RA, Hardegen NJ, Philp D, Kleinman HK, Osa EO, Wang J, Clouse KA, Wahl LM, Hewlett IK, Rappaport J, Yamada KM, Dhawan S.

Peptides. 2006 Apr;27(4):611-21. Epub 2005 Oct 26.

PMID:
16256245

Supplemental Content

Support Center